evidence table
Peppermint Irritable Bowel Syndrome Meta-Analysis Evidence Table
Structured evidence table for Peppermint Irritable Bowel Syndrome Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Peppermint Irritable Bowel Syndrome Meta-Analysis | Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | 1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | Abdominal pain must be associated with two or more of the following: defecation, change in stool frequency, or change in stool form (Rome [Foundation] IV criteria;). | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | The emphasis that NPs and PAs place on holistic, patient-centered care provides increased opportunities for education and counseling, and patients with disorders of gut–brain interaction, such as IBS, would benefit from a collaborative treatment approach that validates their experiences and addresses their most bothersome symptoms (;;). | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | He reported no evidence of rectal bleeding or unintentional weight loss and had no known family history of colorectal cancer, inflammatory bowel disease (IBD), or other GI conditions. | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
| Peppermint Irritable Bowel Syndrome Meta-Analysis | This condition is characterized by recurrent abdominal pain occurring at least 1 day per week, on average, during the previous 3 months, with symptom onset at least 6 months before diagnosis. | 4 | Ladewski Amy M. (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations |
Source documents